National Center for Advancing Translational Sciences

LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 27, 2023
FGFR, National Center for Advancing Translational Sciences, Medicine, Conference on International Exchange of Professionals, LIBRA, Marketing, International Ecological Economy Promotion Association, New Drug Application, Hypertrophic cardiomyopathy, NDA, Oxford Handbook of Clinical Medicine, Joint committee, Lung cancer, RSV, Patient, Diagnosis, Research, FDA, FGFR2, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCM, Food, Disease, Pharmaceutical industry, Video game, Demodex, Pfizer

SHANGHAI, China and PRINCETON, N.J., March 27, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • With a cash runway through the end of 2024, we believe LianBio is well positioned to become a commercial-stage company.
  • LianBio has now filed New Drug Applications to support approval of mavacamten in Hong Kong, Singapore and Macau.
  • In November 2022, LianBio announced the initiation of the Phase 3 LIBRA clinical trial of TP-03 in Demodex blepharitis.
  • Fourth Quarter and Full-Year 2022 Financial Results:
    Research and development expenses were $10.6 million for the fourth quarter of 2022 compared to $7.7 million for the fourth quarter of 2021, and $59.8 million for the year ended December 31, 2022 compared to $158.7 million for the year ended December 31, 2021.

Virpax Pharmaceuticals Reports 2022 Year-End Results

Retrieved on: 
Wednesday, March 22, 2023
Science, Other Science, Biotechnology, Pharmaceutical, Surgery, Health, Infectious Diseases, Other Health, Epilepsy, National Center for Advancing Translational Sciences, Insurance, ChromeOS, Nanoparticle, Central nervous system, FINANCIAL, Paycheck Protection Program, Partner, PIND, Drug discovery, CRADA, NCATS, Brain, CNS, Bangladesh Technical Education Board, Nose, Food and Drug Administration, Olfactory nerve, Daubert v. Merrell Dow Pharmaceuticals, Inc., Patent, Post-traumatic stress disorder, Physician, Pain management, MET, OTC, Cannabidiol, FDA, Research, Chronic pain, IND, NIH, Pain, Food, Safety, Pharmaceutical industry, Medical device, Vaccine, Cryptocurrency

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2022, and other recent developments.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2022, and other recent developments.
  • On December 8, 2022, Virpax received Pre-Investigational New Drug (PIND) application guidance from the FDA for NobrXiol.
  • FINANCIAL RESULTS FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021
    Twelve Months Ended December 31, 2022
    General and administrative expenses increased by $3,896,078, or 54%, to $11,082,463 for the year ended December 31, 2022, from $7,186,385 for the year ended December 31, 2021.
  • At December 31, 2022, Virpax had cash of approximately $19.0 million.

Heart Muscle Tissue Chips Among Life Science Investigations Launching to ISS on SpaceX CRS-27

Retrieved on: 
Wednesday, March 8, 2023
Redwire, SpaceX, Boeing, ISS National Lab, Stanford University, BFF, CRS, Meniscus, Research, Bangladesh Technical Education Board, 3D bioprinting, Crystallization, Biotechnology, International Space Station, SPACE, Heart, Tissue, Partnership, Kennedy Space Center Launch Complex 39A, Kennedy Space Center, Patient, Johns Hopkins University, Commercial Resupply Services, Skeletal muscle, ISS, National Center for Advancing Translational Sciences, Medicine, Bristol Myers Squibb, Temperature, Knowledge, Scientific research on the International Space Station, United States Commercial Service, MassChallenge, NIH, National Center for Research Resources, Pharmaceutical industry, Communications satellite, 3D printing, Science

These projects, sponsored by the ISS National Laboratory, will study microgravity's effects on engineered heart muscle tissue, and results could lead to new treatments for heart disease.

Key Points: 
  • These projects, sponsored by the ISS National Laboratory, will study microgravity's effects on engineered heart muscle tissue, and results could lead to new treatments for heart disease.
  • These projects were funded through the Tissue Chips in Space initiative , a multiyear collaboration between the ISS National Lab and NIH's National Center for Advancing Translational Sciences.
  • Muscles, including the heart, can weaken in microgravity, so heart muscle tissue chips in space could be used to model heart disease and screen potential new drugs.
  • These are only a few of the investigations sponsored by the ISS National Lab that are launching on this mission.

Next SpaceX Mission to International Space Station Includes Research on Cardiac Tissue Chips, Protein Crystals, and Materials for Cost-Effective Satellites

Retrieved on: 
Tuesday, March 7, 2023
Life, SpaceX Dragon, SpaceX, ISS National Lab, Stanford University, CRS, RF, Research, International Space Station, Bangladesh Technical Education Board, Crystallization, SPACE, National Center for Advancing Translational Sciences, Partnership, Kennedy Space Center Launch Complex 39A, Kennedy Space Center, Commerce, Patient, Johns Hopkins University, EDT, Commercial Resupply Services, ISS, Bristol Myers Squibb, Temperature, Knowledge, Scientific research on the International Space Station, 3D, National Center for Functional Glycomics, Communications satellite, Pharmaceutical industry, Medical imaging

The launch is scheduled for no earlier than 8:30 p.m. EDT on March 14, 2023, from Launch Complex 39A at Kennedy Space Center in Florida.

Key Points: 
  • The launch is scheduled for no earlier than 8:30 p.m. EDT on March 14, 2023, from Launch Complex 39A at Kennedy Space Center in Florida.
  • Both teams have previously launched tissue chip investigations to the space station, and these latest projects will build on prior knowledge gained.
  • Through this project, L3Harris seeks to test 3D-printed radio frequency (RF) circuits, RF communications systems, and other materials for developing smaller, more cost-effective satellites.
  • To learn more about all ISS National Lab-sponsored investigations on this mission, please visit the SpaceX CRS-27 mission overview page .

Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline

Retrieved on: 
Tuesday, March 7, 2023
MBA, National Center for Advancing Translational Sciences, Research, Biomarker, Clinical trial, Incyte, DNA, Partnership, Patient, Cancer, Medicine, Sequence, RNA, Pharmaceutical industry, Medical imaging

IRVING, Texas, March 7, 2023 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced a strategic research partnership with Incyte Corporation (NASDAQ:INCY) to augment precision medicine approaches for Incyte's oncology pipeline.

Key Points: 
  • IRVING, Texas, March 7, 2023 /PRNewswire/ -- Caris Life Sciences ®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced a strategic research partnership with Incyte Corporation (NASDAQ:INCY) to augment precision medicine approaches for Incyte's oncology pipeline.
  • "This partnership with Incyte will leverage Caris' leading molecular science and technology solutions to support Incyte's oncology research and development efforts," said David Spetzler , M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences.
  • Incyte will also leverage Caris' biomarker-driven patient selection for clinical trials including options to partner on developing companion diagnostics for programs in the partnership.
  • "Our partnership with Caris will bring a comprehensive suite of precision medicine capabilities to augment Incyte's success in developing key programs in our robust oncology portfolio."

Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
NGS, JD, Depreciation, Doctor of Philosophy, DNA, MBBS, Merck, National Center for Advancing Translational Sciences, General Administration of Press and Publication, Genomics, Metabolism, Investigational New Drug, Workforce, Partnership, IND, IEM, EPI, Terminal deoxynucleotidyl transferase, Exocrine pancreatic insufficiency, Steatorrhea, Mass meeting, Patient, R, Fabry disease, MAI, Enzyme, PKU, Probability, Synthetic biology, ROFN, Serum, Doctor of Science, Takeda Pharmaceutical Company, General counsel, Rhode Island Division of Commercial Licensing and Regulation, Administration, Roche, Cryptocurrency, Pharmaceutical industry, Fine chemical, Video game, Phenylketonuria, Takeda, Fabry, Codexis, Science

REDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.

Key Points: 
  • Total revenues for the fourth quarter 2022 were $30.4 million, an increase of 24% from $24.5 million in the fourth quarter 2021.
  • R&D revenues for the fourth quarter 2022 were $7.1 million compared to $7.5 million in the fourth quarter 2021.
  • Product gross margin for the fourth quarter 2022 was 64% compared to 60% in the fourth quarter 2021, driven by changes in sales mix.
  • Selling, General & Administrative expenses for the fourth quarter 2022 were $12.3 million, compared to $11.7 million in the fourth quarter 2021.

Pandemic Antiviral Discovery (PAD) makes first investments to support the development of new antiviral medicines for future pandemics

Retrieved on: 
Thursday, February 23, 2023
Discovery, Hendra virus, Fatality, Pandemic, Bill, Senior, Nipah virus, Disease, Henipavirus, Drug development, National Center for Advancing Translational Sciences, Virus, Drug discovery, Research, Nipa, Investment, Novo Nordisk Foundation, PAD, Human, RFP, Bill & Melinda Gates Foundation, Infection, COVID-19, Open Philanthropy (organization), Vaccine, Pharmaceutical industry

COPENHAGEN, Denmark, Feb. 23, 2023 /PRNewswire/ -- Today, the partners in Pandemic Antiviral Discovery (PAD) initiative announced grants totalling more than USD 26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in humans.

Key Points: 
  • Its purpose is to accelerate the discovery and development of antiviral drugs for future pandemic threats.
  • With equitable access as a core principle of the initiative, PAD is focused on ensuring these interventions are accessible to people in low- and middle-income countries.
  • "Preparing for future pandemics means investing in the discovery of lifesaving interventions before viruses of concern escalate into deadly pandemics and ensuring those tools will be readily available to anyone who needs them."
  • To pave the way for the development of such antiviral drugs, greater knowledge of the henipavirus subfamily is needed.

Pandemic Antiviral Discovery (PAD) makes first investments to support the development of new antiviral medicines for future pandemics

Retrieved on: 
Thursday, February 23, 2023
Discovery, Hendra virus, Fatality, Pandemic, Bill, Senior, Nipah virus, Disease, Henipavirus, Drug development, National Center for Advancing Translational Sciences, Virus, Drug discovery, Research, Nipa, Investment, Novo Nordisk Foundation, PAD, Human, RFP, Bill & Melinda Gates Foundation, Infection, COVID-19, Open Philanthropy (organization), Vaccine, Pharmaceutical industry

COPENHAGEN, Denmark, Feb. 23, 2023 /PRNewswire/ -- Today, the partners in Pandemic Antiviral Discovery (PAD) initiative announced grants totalling more than USD 26 million for 14 research projects aimed at facilitating early-stage development of drugs to treat henipavirus infection and disease in humans.

Key Points: 
  • Its purpose is to accelerate the discovery and development of antiviral drugs for future pandemic threats.
  • With equitable access as a core principle of the initiative, PAD is focused on ensuring these interventions are accessible to people in low- and middle-income countries.
  • "Preparing for future pandemics means investing in the discovery of lifesaving interventions before viruses of concern escalate into deadly pandemics and ensuring those tools will be readily available to anyone who needs them."
  • To pave the way for the development of such antiviral drugs, greater knowledge of the henipavirus subfamily is needed.

Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Pharmaceutical, Health, Patent, Central nervous system disease, Bangladesh Technical Education Board, NIH, Pain, National Center for Advancing Translational Sciences, Chronic pain, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Liver, Post-traumatic stress disorder, CNS, Pain management, Knowledge, MET, NCATS, Central nervous system, Pharmaceutical industry, Vaccine

Envelta is Virpax’s non-opioid pain product candidate for acute and chronic pain including non-cancer pain.

Key Points: 
  • Envelta is Virpax’s non-opioid pain product candidate for acute and chronic pain including non-cancer pain.
  • “We have engaged New England Investors, a life-sciences advisory firm, to represent us in our licensing efforts in China for Envelta,” stated Anthony P. Mack , Chairman and CEO of Virpax Pharmaceuticals.
  • “New England Investors has offices in the United States along with mainland China and Singapore.
  • A patent for Envelta has recently been filed in China and we intend to begin our efforts with our Chinese colleagues shortly,” commented Mr. David Place, Managing Director of New England Investors, LLC.

Sapphiros Taps Teresa Abraham for VP of Scientific and Technical Affairs

Retrieved on: 
Wednesday, January 25, 2023
Science, MED, AAAS, Policy, University, National Center for Advancing Translational Sciences, KKR, Visby, Office of Inspector General, U.S. Department of Health and Human Services, Bureau of Oceans and International Environmental and Scientific Affairs, Government, Human services, Health equity, Federation, U.S. Department of Defense Strategy for Operating in Cyberspace, Silicon, Doctor of Philosophy, American Association for Clinical Chemistry, Management, Medical device

BOSTON, Jan. 25, 2023 /PRNewswire/ -- Sapphiros, a platform dedicated to building the next generation of consumer diagnostics, backed by KKR, is pleased to announce the appointment of Teresa Abraham, PhD, as its new Vice President of Scientific and Technical Affairs.

Key Points: 
  • BOSTON, Jan. 25, 2023 /PRNewswire/ -- Sapphiros, a platform dedicated to building the next generation of consumer diagnostics, backed by KKR, is pleased to announce the appointment of Teresa Abraham, PhD, as its new Vice President of Scientific and Technical Affairs.
  • Dr. Abraham will be responsible for partnerships that accelerate technology development and clinical research for a portfolio of Med Tech companies under the Sapphiros umbrella.
  • She brings a wealth of experience in scientific research, technical development, and policy advocacy.
  • Prior to joining Sapphiros, Dr. Abraham was VP of Scientific and Technical Partnerships at Visby Medical in San Jose, CA, where she secured over $70 million in non-dilutive funding to accelerate platform and product development.